Recce is raising up to A$15.8m in equity fundraising through a now-completed A$5.0m share placement and an entitlement offer for remaining shareholders that could raise up to an additional A$10.8m in gross proceeds. Both rounds of financing are priced at A$0.28 per new share. We anticipate the tota

23 Apr 2025
Funding secured to start Phase III pivotal trials

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Funding secured to start Phase III pivotal trials
Recce Pharmaceuticals Ltd. (RCE:ASX) | 0 0 -5.6% | Mkt Cap: 14.9m
- Published:
23 Apr 2025 -
Author:
Jyoti Prakash, CFA | Pooya Hemami, OD MBA, CFA -
Pages:
6 -
Recce is raising up to A$15.8m in equity fundraising through a now-completed A$5.0m share placement and an entitlement offer for remaining shareholders that could raise up to an additional A$10.8m in gross proceeds. Both rounds of financing are priced at A$0.28 per new share. We anticipate the tota